AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own BlackSky, you need to believe that rapid expansion of its Gen-3 constellation and AI analytics can convert early access demand into durable, higher quality recurring revenue. The latest three-week commissioning milestone reinforces the near term catalyst around Gen-3 adoption, but it does not remove the key risk that revenue and cash flow remain volatile if trials fail to convert or if spending on new constellations and acquisitions keeps pressuring the balance sheet.
The recent US$100 million at the market follow on equity filing is particularly relevant here, as it directly affects how BlackSky funds its Gen-3 and Arrow build outs while still being unprofitable. For investors, this ties the upside from faster capacity deployment to very real questions about future dilution, earnings per share pressure, and how quickly new satellites can translate into sustainable cash generation.
Yet investors should also be aware that equity raises and heavy constellation spending could still...
Read the full narrative on BlackSky Technology (it's free!)
BlackSky Technology's narrative projects $230.4 million revenue and $16.4 million earnings by 2028.
Uncover how BlackSky Technology's forecasts yield a $27.29 fair value, a 42% upside to its current price.
Nine Simply Wall St Community fair value estimates for BlackSky span roughly US$8 to US$69 per share, showing how far apart individual views can be. Set against this, the company’s heavy capital needs for Gen 3 and Arrow expansion make it important for you to weigh several different opinions before deciding how that growth potential might affect future returns.
Explore 9 other fair value estimates on BlackSky Technology - why the stock might be worth over 3x more than the current price!
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.
Every day counts. These free picks are already gaining attention. See them before the crowd does:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com